Literature DB >> 3694178

Immune enhancement of yellow fever virus neurovirulence for mice: studies of mechanisms involved.

E A Gould1, A Buckley, B K Groeger, P A Cane, M Doenhoff.   

Abstract

Enhancement of yellow fever virus neurovirulence for mice by specific antibody was studied with the French neurotropic vaccine strain. Experimental conditions for enhancement required mice between 14 and 40 days old and intraperitoneal administration of a selected monoclonal antibody 24 h before or up to 72 h after intracerebral virus challenge. Virus infectivity titrations were similar in brains of antibody-treated and untreated mice. Virus recovered from brains of mice with enhanced viral infections was neither qualitatively nor quantitatively different from standard virus. Humoral immune responses in enhanced infections were normal, macrophages did not become infected and viraemia was not significant. Both hydrocortisone treatment and complement depletion with cobra venom resulted in prolongation of mouse survival times but virulence enhancement persisted. Antithymocyte serum had no effect on enhancement although it reduced the humoral immune response. It is proposed that virulence enhancement is due to the combined effects of virus-specific antibody on infected cells, complement-mediated cytolysis and resultant host anti-cellular activity. There is no analogy between mechanisms effecting increased arbovirus growth in vitro in the presence of specific antibody and increased yellow fever virus neurovirulence in vivo after parenteral administration of antibody.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3694178     DOI: 10.1099/0022-1317-68-12-3105

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

1.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

2.  A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Authors:  Brett A Thibodeaux; Nina C Garbino; Nathan M Liss; Joseph Piper; Jacob J Schlesinger; Carol D Blair; John T Roehrig
Journal:  Antiviral Res       Date:  2012-02-15       Impact factor: 5.970

3.  Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology.

Authors:  Kerrie Vaughan; Jason Greenbaum; Martin Blythe; Bjoern Peters; Alessandro Sette
Journal:  Viral Immunol       Date:  2010-06       Impact factor: 2.257

Review 4.  A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.

Authors:  Boopathy Ramakrishnan; Karthik Viswanathan; Kannan Tharakaraman; Vlado Dančík; Rahul Raman; Gregory J Babcock; Zachary Shriver; Ram Sasisekharan
Journal:  Trends Microbiol       Date:  2016-10-14       Impact factor: 17.079

5.  Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies.

Authors:  J Arikawa; J S Yao; K Yoshimatsu; I Takashima; N Hashimoto
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

6.  Neutralizing-enhancing monoclonal antibody recognizes the denatured glycoprotein of viral haemorrhagic septicaemia virus.

Authors:  F Sanz; J M Coll
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

7.  Interaction of immune complexes isolated from hepatitis C virus-infected individuals with human cell lines.

Authors:  Rafael Marino; Leopoldo Deibis; Juan B De Sanctis; Nicolas E Bianco; Felix Toro
Journal:  Med Microbiol Immunol       Date:  2005-01       Impact factor: 3.402

Review 8.  Progress on the development of therapeutics against West Nile virus.

Authors:  Michael S Diamond
Journal:  Antiviral Res       Date:  2009-06-06       Impact factor: 5.970

9.  Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice.

Authors:  Michael J Engle; Michael S Diamond
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  The NS1 glycoprotein can generate dramatic antibody-enhanced dengue viral replication in normal out-bred mice resulting in lethal multi-organ disease.

Authors:  Andrew K I Falconar; Fernando Martinez
Journal:  PLoS One       Date:  2011-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.